Abstract
Although thoracic ablative therapies are generally safe procedures, fatal complications can occur. Bevacizumab is a standard-of-care treatment along with chemotherapy for metastatic colorectal cancer. Although uncommon, unpredictable serious adverse events can occur secondary to bevacizumab. We report a case of fatal intrapulmonary haemorrhage as a result of arteriopulmonary fistula in a patient after microwave ablation of pulmonary colorectal cancer metastasis while on bevacizumab. Antiangiogenetic properties of bevacizumab are associated with delayed wound healing, which might have been a crucial factor in the development of arteriopulmonary fistula and haemorrhage.
Original language | English |
---|---|
Pages (from-to) | 514-515 |
Number of pages | 2 |
Journal | Interdisciplinary cardiovascular and thoracic surgery |
Volume | 26 |
Issue number | 3 |
DOIs | |
Publication status | Published - 1 Mar 2018 |